SolasCure is moving forward with its maggot-derived wound gel, after publishing the results of its recent phase 2 clinical trial in a leading wound care journal.
California-based biotech company Metabolomycs has released a new study demonstrating how pancreatic cancer could be diagnosed earlier with a blood test.
Biogen’s stance at the upcoming AD/PD 2024 International Conference on Alzheimer’s disease and Parkinson’s disease will demonstrate its future plans for treating Alzheimer’s, following the discontinuation of Aduhelm (aducanumab), its anti-amyloid beta...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently refused marketing authorization for Nezglyal (leriglitazone).
OneChain Immunotherapeutics has received €1.9m from the Spanish Ministry of Science and Innovation to advance a ‘groundbreaking’ CAR-T therapy for acute lymphoblastic leukemia type T into clinical development.
Finnish health technology company Solu has launched an online tool to analyse and prevent outbreaks of Candida auris disease, which it claims is the fastest on the market.
Allecra Therapeutics, a biopharma company developing novel therapies to combat antibiotic resistance, has received FDA approval for its treatment tackling ‘complicated’ urinary tract infections (UTIs).
Baseimmune, a biotech company that uses proprietary, deep learning AI to predict future pathogen mutations to generate novel vaccines, has closed its $11.3 million Series A funding round.
Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the first launch of BRIUMVI (ublituximab) in Europe for the treatment of adult patients with relapsing multiple...
The Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Janssen’s CARVYKTI (cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM).
AN2 Therapeutics recently announced a decision to voluntarily pause enrollment of the phase 3 portion of the phase 2/3 trial, EBO-301, in light of potentially lower than expected efficacy data obtained from the phase 2 trial.
Biora Therapeutics recently announced the initiation of phase 1 clinical trials of BT-600, a novel drug-device combination for ulcerative colitis (UC) patients.
Novo Nordisk is set to acquire three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, has been awarded Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) by the United States Food and Drug Administration (FDA).
The father of a boy diagnosed with acute lymphoblastic leukemia at the age of nine, inspired by his son's love of collecting, has created patches of positivity for children going through cancer treatment to collect.
A bipartisan group of US lawmakers is urging the Biden administration to conduct a formal investigation and place sanctions against biotech firm WuXi AppTec, citing its connections to the Chinese military.
TILT Biotherapeutics, a clinical-stage biotech company developing cancer immunotherapies, has received a $2 million grant from the U.S. Department of Defense (DOD) for a three-year project to treat ovarian cancer using its TILT-123 asset.
The US FDA has granted fast track designation to CAN-3110, a viral immunotherapy candidate from Candel Therapeutics to treat patients with recurrent high-grade glioma (HGG) and improve overall survival.
Following positive advice from the Scottish Medicines Consortium (SMC), the first biologic treatment for inflammatory skin disease, hidradenitis suppurativa (HS), is now available in Scotland on the NHS.
Alys Pharmaceuticals, an immuno-dermatology focused company, has launched with $100 million financing by Medicxi and an R&D pipeline enabled by multiple platform technologies.
Sano Chemicals has begun its phase 1, first-in-human clinical trial of Occidiofungin, a new treatment to cure recurrent vaginal yeast infections or vulvovaginal candidiasis (RVVC).
Vicore Pharma has entered into an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku to commercialize Vicore’s idiopathic pulmonary fibrosis (IPF) drug candidate C21 in Japan.
Just – Evotec Biologics has expanded its relationship with Advanced BioScience Laboratories (ABL), a global CDMO serving the US Government and biopharmaceutical industry.
GSK’s vaccine Arexvy is currently undergoing regulatory review with the potential of being approved in Europe for use in adults aged between 50 and 59 who are at an increased risk for respiratory syncytial virus (RSV) infection.
In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made history by gaining the first FDA approval for a CRISPR-based drug, exagamglogene autotemcel (Casgevy) for the treatment of sickle cell disease with vaso-occlusive crisis.
Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.
Orano Med, a biotech firm developing targeted alpha therapies for oncology, has announced the launch of its ATLab (alpha therapy laboratory) in Onnaing, France.
Synthetic biology company Asimov has launched its new LV edge packaging system, which it claims will improve the cost efficiency and reduce the supply chain risk of lentiviral production.
Biotechnology company Vergent Bioscience has revealed that VGT-309, its investigational tumor-targeted fluorescent imaging agent, is able to help surgeons see lung tumors in real time during surgical procedures.
Colleen Acosta is CEO of Freya Biosciences which is a trans-Atlantic clinical-stage biotech company pioneering microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of women’s reproductive system conditions and we were...
We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.
Dermatology biopharma company Arcutis has launched ZORYVE, a topical foam for the treatment of seborrheic dermatitis, in the United States for individuals 9 years of age and older.
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and the Flow Cytometry Facility at the Babraham Institute have announced a collaboration to develop a bespoke cell phenotyping...
Danish biotech company Vesper Bio has been awarded a grant worth $873,000 by The Michael J. Fox Foundation (MJFF) to assess sortilin inhibition in Parkinson’s disease.
Stimulants, amphetamines, and methylphenidates are currently the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major global markets; France, Germany, Italy, Spain, the UK, the US, and Japan....